File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The α1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway

TitleThe α1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway
The alpha1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway
Authors
Issue Date2003
PublisherDemetrios A Spandidos Ed & Pub. The Journal's web site is located at http://147.52.72.117/OR/or.htm
Citation
Oncology Reports, 2003, v. 10 n. 5, p. 1555-1560 How to Cite?
AbstractProstate cancer is the second leading cause of cancer-related death in men. Treatment failure in prostate cancer is usually due to the development of androgen independence and resistance to chemotherapeutic drugs at an advanced stage. Recently, it was reported that the alpha1-adrenoceptor antagonist terazosin was able to inhibit prostate cancer cell growth and indicated that it may have an implication in the treatment of prostate cancer. The aim of the present study was to investigate the mechanisms involved in terazosin-induced prostate cancer cell death using two androgen-independent cell lines, PC-3 and DU145. Our results showed that terazosin inhibited not only prostate cancer cell growth but also colony forming ability, which is the main target of chemotherapy. We also found that the sensitivity of these cells to terazosin was not affected by the presence of either functional p53 or Rb, suggesting that the terazosin-induced cell death was independent of p53 and Rb. However, the terazosin-induced cell death was associated with G1 phase cell cycle arrest and up-regulation of p27KIP1. In addition, up-regulation of Bax and down-regulation of Bcl-2 was also observed indicating that these two apoptotic regulators may play important roles in terazosin-mediated cell death pathway. Our results provide evidence for the first time that terazosin may have a therapeutic potential in the treatment of advanced prostate cancer.
Persistent Identifierhttp://hdl.handle.net/10722/149637
ISSN
2015 Impact Factor: 2.486
2015 SCImago Journal Rankings: 0.968
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorXu, Ken_US
dc.contributor.authorWang, Xen_US
dc.contributor.authorLing, PMen_US
dc.contributor.authorTsao, SWen_US
dc.contributor.authorWong, YCen_US
dc.date.accessioned2012-06-26T05:56:21Z-
dc.date.available2012-06-26T05:56:21Z-
dc.date.issued2003en_US
dc.identifier.citationOncology Reports, 2003, v. 10 n. 5, p. 1555-1560en_US
dc.identifier.issn1021-335Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/149637-
dc.description.abstractProstate cancer is the second leading cause of cancer-related death in men. Treatment failure in prostate cancer is usually due to the development of androgen independence and resistance to chemotherapeutic drugs at an advanced stage. Recently, it was reported that the alpha1-adrenoceptor antagonist terazosin was able to inhibit prostate cancer cell growth and indicated that it may have an implication in the treatment of prostate cancer. The aim of the present study was to investigate the mechanisms involved in terazosin-induced prostate cancer cell death using two androgen-independent cell lines, PC-3 and DU145. Our results showed that terazosin inhibited not only prostate cancer cell growth but also colony forming ability, which is the main target of chemotherapy. We also found that the sensitivity of these cells to terazosin was not affected by the presence of either functional p53 or Rb, suggesting that the terazosin-induced cell death was independent of p53 and Rb. However, the terazosin-induced cell death was associated with G1 phase cell cycle arrest and up-regulation of p27KIP1. In addition, up-regulation of Bax and down-regulation of Bcl-2 was also observed indicating that these two apoptotic regulators may play important roles in terazosin-mediated cell death pathway. Our results provide evidence for the first time that terazosin may have a therapeutic potential in the treatment of advanced prostate cancer.en_US
dc.languageengen_US
dc.publisherDemetrios A Spandidos Ed & Pub. The Journal's web site is located at http://147.52.72.117/OR/or.htmen_US
dc.relation.ispartofOncology reportsen_US
dc.subject.meshAdrenergic Alpha-1 Receptor Antagonistsen_US
dc.subject.meshBlotting, Westernen_US
dc.subject.meshCell Cycleen_US
dc.subject.meshCell Cycle Proteins - Biosynthesisen_US
dc.subject.meshCell Deathen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshCell Survivalen_US
dc.subject.meshColony-Forming Units Assayen_US
dc.subject.meshCyclin-Dependent Kinase Inhibitor P27en_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshFlow Cytometryen_US
dc.subject.meshG1 Phaseen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshPrazosin - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshProstatic Neoplasms - Drug Therapyen_US
dc.subject.meshRetinoblastoma Protein - Metabolismen_US
dc.subject.meshTransfectionen_US
dc.subject.meshTumor Suppressor Protein P53 - Metabolismen_US
dc.subject.meshTumor Suppressor Proteins - Biosynthesisen_US
dc.subject.meshUp-Regulationen_US
dc.titleThe α1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathwayen_US
dc.titleThe alpha1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway-
dc.typeArticleen_US
dc.identifier.emailTsao, SW:gswtsao@hkucc.hku.hken_US
dc.identifier.emailWong, YC:ycwong@hkucc.hku.hken_US
dc.identifier.authorityTsao, SW=rp00399en_US
dc.identifier.authorityWong, YC=rp00316en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.3892/or.10.5.1555-
dc.identifier.pmid12883741-
dc.identifier.scopuseid_2-s2.0-2142800081en_US
dc.identifier.hkuros88936-
dc.identifier.volume10en_US
dc.identifier.issue5en_US
dc.identifier.spage1555en_US
dc.identifier.epage1560en_US
dc.identifier.isiWOS:000184463500082-
dc.publisher.placeGreeceen_US
dc.identifier.scopusauthoridXu, K=7403282051en_US
dc.identifier.scopusauthoridWang, X=7501854829en_US
dc.identifier.scopusauthoridLing, PM=7103218614en_US
dc.identifier.scopusauthoridTsao, SW=7102813116en_US
dc.identifier.scopusauthoridWong, YC=7403041798en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats